Blurbs

Analysts Offer Insights on Technology Companies: BAE Systems (OtherBAESF), Marvell (MRVL) and Health Catalyst (HCAT)

Analysts have been eager to weigh in on the Technology sector with new ratings on BAE Systems (BAESFResearch Report), Marvell (MRVLResearch Report) and Health Catalyst (HCATResearch Report).

BAE Systems (BAESF)

In a report released yesterday, David Perry from J.P. Morgan downgraded BAE Systems to Hold, with a price target of p965.00. The company’s shares closed last Friday at $9.61.

Perry has an average return of 1.9% when recommending BAE Systems.

According to TipRanks.com, Perry is ranked #7631 out of 8001 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BAE Systems with a $11.54 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Marvell (MRVL)

In a report issued on August 26, Harlan Sur from J.P. Morgan maintained a Buy rating on Marvell, with a price target of $85.00. The company’s shares closed last Friday at $50.17.

According to TipRanks.com, Sur is a 5-star analyst with an average return of 16.6% and a 59.4% success rate. Sur covers the Technology sector, focusing on stocks such as Advanced Micro Devices, GlobalFoundries Inc, and NXP Semiconductors.

Marvell has an analyst consensus of Strong Buy, with a price target consensus of $72.68, representing a 34.0% upside. In a report issued on August 26, KeyBanc also maintained a Buy rating on the stock with a $75.00 price target.

Health Catalyst (HCAT)

J.P. Morgan analyst Anne Samuel upgraded Health Catalyst to Buy yesterday and set a price target of $16.00. The company’s shares closed last Friday at $12.04, close to its 52-week low of $10.95.

According to TipRanks.com, Samuel is a 4-star analyst with an average return of 22.3% and a 48.0% success rate. Samuel covers the Technology sector, focusing on stocks such as Definitive Healthcare Corp, Convey Holding Parent, and Change Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Health Catalyst with a $18.86 average price target, implying a 54.3% upside from current levels. In a report issued on August 16, Berenberg Bank also maintained a Buy rating on the stock with a $17.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BAESF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos